Open AccessTreatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
Author(s) -
Peter Martin,
Jonathon B. Cohen,
Michael L. Wang,
Anita Kumar,
Brian T. Hill,
Diego Villa,
Jeffrey M. Switchenko,
Brad S. Kahl,
Kami J. Maddocks,
Natalie S. Grover,
Keqin Qi,
Lori Parisi,
K. Daly,
Angeline Zhu,
Gilles Salles
Publication year - 2023
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.02698
Subject(s) - medicine , mantle cell lymphoma , rituximab , autologous stem cell transplantation , hazard ratio , cohort , bendamustine , chemoimmunotherapy , oncology , cytarabine , retrospective cohort study , transplantation , surgery , lymphoma , chemotherapy , confidence interval
Commonly used first-line (1L) treatments for mantle cell lymphoma include high-dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for younger patients and several chemoimmunotherapy regimens for older patients. Continuous debates exist on the role of ASCT in younger patients and maintenance rituximab (MR) after bendamustine plus rituximab (BR).